Protein Reverses Vascular And Nerve Damage In Diabetic Rats

July 24, 1997

St.. Louis, July 24, 1997 -- A small protein once thought to be a useless waste product may effectively prevent and even reverse cardiovascular disease and nerve damage in diabetics, researchers at Washington University School of Medicine in St. Louis announced today.

In a joint study with Eli Lilly and Company, the researchers found that treatment with a human protein called C-peptide repaired damaged blood vessels and nerves in diabetic rats. The protein, a by-product of the production of insulin, is present in non-diabetic people but scarce or absent in type I (insulin-dependent) diabetics.

The protein is exciting for the sheer novelty of its effects as well as its therapeutic potential. Its modus operandi seems to be unprecedented, suggesting that the long-accepted view of how proteins affect cell function is far from the whole story. The study is described in the July 25, 1997, issue of Science.

"Some researchers had suspected that C-peptide might have some biological action, but it was difficult to prove," says Yasuo Ido, Ph.D., a research associate of pathology at the School of Medicine and lead author of the paper. "We found that not only does it have biological effects, these effects may be extremely important for protecting the heart, nerves, and arteries."

The protein is already abundant in many pharmaceutical laboratories, Ido says. Whenever insulin is manufactured, whether in the body or in a lab, C-peptide is released as a by-product. If the protein proves to be effective for human diabetics, the by-product might one day be almost as prized as the insulin.

Type I (insulin-dependent) and type II (non-insulin-dependent) diabetes each greatly increase the risk of nerve damage and cardiovascular disease. For unknown reasons, glucose imbalances in diabetic tissues lead to widespread damage of nerve cells and cells that line blood vessels. The damaged blood vessels become leaky, allowing cholesterol to seep in and set the stage for atherosclerosis and dangerous vascular occlusions. According to the Centers for Disease Control, diabetics are two to three times more likely than other people to die of atherosclerosis or other cardiovascular complications in a given year.

Beginning in the 1970's, some researchers wondered if diabetics might be suffering from a lack of C-peptide, which is normally secreted by the pancreas in concert with insulin. In 1993, Julio Santiago, M.D., professor of medicine and pediatrics at the School of Medicine, injected human diabetics with low doses of the protein -- just enough to match normal levels -- but saw no effects.

Trying a different approach, Ido and colleagues injected diabetic rats with larger doses of synthetic human C-peptide, exceeding the levels of C-peptide that rats produce naturally. The results were dramatic: Nerve cells worked normally and vessels almost completely stopped leaking. Because relatively large doses were needed to achieve the effect, researchers suspect C-peptide therapy could also help type II (non-insulin-dependent) diabetics who already have normal levels of the protein.

"Since this protein is so effective at preventing and reversing vascular leakage, it brings up the possibility that it could prevent cardiovascular disease in both types of diabetes," says Joseph R. Williamson, M.D., professor of pathology at the School of Medicine and senior researcher of the study. Type 1 diabetics would still have to take insulin, but they might not have to be so concerned about maintaining absolutely normal glucose levels to prevent vascular and nerve damage, he says.

Despite the impressive results, the researchers faced a significant problem. "We had a hard time convincing people of our findings, because the protein obviously wasn't working in the usual way," Ido says. Most researchers assumed that C-peptide, if it did anything at all, must work by fitting into a specific receptor like a key fits into a lock. Many investigators, including Ido, searched for a receptor for C-peptide without success. "It was hard to believe that C-peptide could do anything without a receptor," he said.

Researchers eventually used a molecular trick to prove that C-peptide didn't need a receptor. They made a mirror-image of the protein by reversing each of its building-block amino acids. If the protein worked like a key, its mirror-image analog would be useless because it wouldn't fit in the lock. To their astonishment, the researchers found that the mirror image of C-peptide also prevented vascular damage.

Researchers know that C-peptide binds to cell membranes, but they can only guess how it changes the cell. Paul Schlesinger, M.D., Ph.D., an associate professor of cell biology and physiology at the School of Medicine, found that C-peptide strongly affected the flow of potassium ions through artificial membranes. Perhaps, Williamson says, C-peptide helps restore a delicate electrical and ion balance in cells that is disrupted by diabetes. Researchers need to look much closer at C-peptide -- and develop a better understanding of how diabetes damages cells -- before they can determine the function of the protein, he says.
-end-


Washington University School of Medicine

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.